Improving the Lives of Cancer Patients through Research & Discovery
At University Hospitals Seidman Cancer Center, our sole purpose is to improve the lives of cancer patients.
Transformational innovative research is intrinsic to our philosophy of providing the best care for our patients.
It all begins with an idea. Here at UH Seidman Cancer Center and Case Western Reserve University Department of Radiation Oncology, we don't simply want to read the guidelines...we want to create content that helps the lives of cancer patients that changes the guidelines. From bench to bedside to community outreach, we believe good is never good enough; cancer will rest for no one, and neither will we.
Corey Speers, MD, PhD
Vice Chair of Research, Radiation Oncology
Director of the Phase I Clinical Trials Program
Associate Professor at Case Western Reserve University
Case Comprehensive Cancer Center
University Hospitals Seidman Cancer Center is one of the best cancer hospitals in the country for over 20 consecutive years by U.S. News & World Report.
UH Seidman Cancer Center is part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine – one of an elite group of 53 such comprehensive cancer hospitals in the U.S. The Case Comprehensive Cancer Center has an “Exceptional” rating from the NCI, a rating only seven NCI-designated comprehensive cancer centers currently hold.
Pioneering Cutting-Edge Technology and Clinical Trials
UH Seidman Cancer Center’s Department of Radiation Oncology has also pioneered numerous cutting-edge technologies and treatments through our dedication to the design and conduct of clinical trials.
Our Research Includes:
New Combination Therapy for Patients with Non-Small Cell Lung Cancer
Our team at UH Seidman Cancer Center led a novel phase I clinical trial adding a base-excision repair inhibitor TRC102 to chemoradiotherapy for non-small cell lung cancer with exciting results to move to a phase II trial. Read Study Results
Artificial Intelligence (AI) Biomarkers
UH Seidman Cancer Center and Case Western Reserve University helped lead the development and validation with Artera and NRG, the first predictive biomarker to guide ADT use in prostate cancer. Read More
Lead Site for STAMPEDE North America
STAMPEDE is the largest and most successful multi-arm multi-stage trial in the history of prostate run through the United Kingdom. UH Seidman Cancer Center and Case Western Reserve University will lead the expansion of the next phase of the STAMPEDE trial and will now involve North American sites. Read More
Big Data
Leveraging big data we interrogate unrecognized observations. For example, from 253,422 patients treated at 1289 facilities to understand the interplay of facility volume and patient outcomes and the improved outcomes from treatments at higher volume centers. Read Study Results
Metastatic Phenotypes- STARS
We have created a novel staging system, based on features that all metastatic cancer patients have in common. The primary tumor is important, but it's not the only important feature and we believe there is underlying common biology across these metastatic phenotypes. See the App
New Option for Recurrent Breast Cancer
Our team led a prospective study to demonstrate that women may be able to avoid mastectomy for recurrent breast cancer and instead use a far less morbid radiotherapy treatment with partial breast IORT. Read Study Results
Meta-Analysis of Randomized trials of CAncer of the Prostate (MARCAP)
-UH Seidman Cancer Center and UCLA are the two international data repositories for the MARCAP consortium. This is the largest consortium of its kind for prostate cancer of over 20 randomized phase III trials. Learn More